US4622221004 - Common Stock
IONIS PHARMACEUTICALS INC
NASDAQ:IONS (5/1/2024, 9:24:59 AM)
41.86
+0.6 (+1.45%)
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 796 full-time employees. The firm is primarily focused on cardiovascular and neurology franchises. The Company’s products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The firm has over seven medicines in Phase III studies for nine indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)), Tofersen (SOD1) and Bepirovirsen. Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, Fesomersen, ION904 and IONIS-AGT-LRx.
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010
P: 17609319200
CEO: Brett P. MONIA
Employees: 796
Website: https://www.ionispharma.com/
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present positive Phase 3 Balance results in patients with familial...
Here you can normally see the latest stock twits on IONS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: